ARCUTIS BIOTHERAPEUTICS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $2.86 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-02-25
- ARCUTIS BIOTHERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00.
- ARCUTIS BIOTHERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-12-31 was $0.00.
- ARCUTIS BIOTHERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-12-31 was $0.00.
- ARCUTIS BIOTHERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-09-30 was $0.00.
- ARCUTIS BIOTHERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $2.86M.
- ARCUTIS BIOTHERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $0.00.
- ARCUTIS BIOTHERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $0.00.
- ARCUTIS BIOTHERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $0.00.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $2.86M 10-K · filed 2026-02-25 | ||
| 2025-09-30 | $2.86M 10-Q · filed 2025-10-28 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 10-K · filed 2026-02-25 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-10-28 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-25 | |||
| 2022-12-31 | $0.00 10-K · filed 2023-02-28 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $0.00 10-K · filed 2023-02-28 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | ||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-05 | |||
| 2020-12-31 | -$28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$28.00K derived: sum of 2 quarters · filed 2023-02-28 | $3.62M derived: sum of 3 quarters · filed 2023-02-28 | $3.62M 10-K · filed 2023-02-28 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $3.65M derived: sum of 2 quarters · filed 2021-11-04 | $3.65M 10-Q · filed 2021-11-04 | $3.65M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | $3.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $3.65M 10-Q · filed 2021-08-05 | $3.65M derived: sum of 3 quarters · filed 2022-02-22 | $3.65M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-12 | $0.00 derived: sum of 2 quarters · filed 2022-02-22 | $0.00 derived: sum of 3 quarters · filed 2022-02-22 | $0.00 derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $0.00 derived: sum of 2 quarters · filed 2022-02-22 | $0.00 derived: sum of 3 quarters · filed 2022-02-22 | $391.00K 10-K · filed 2022-02-22 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $391.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $391.00K 10-Q · filed 2020-08-11 | ||
| 2019-03-31 | $391.00K 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |